Ali YM, Sweeney J, Shen P, et al. - As for peritoneal mesothelioma, cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) is an accepted treatment, researchers here investigated 46 patients (52.8 ± 13.8 years of age; 52% male) who underwent HIPEC for peritoneal mesothelioma to determine their QOL after HIPEC. The patients participated in QOL surveys, including completion of the Short Form-36, Functional Assessment of Cancer Therapy + Colon, Brief Pain Inventory, and Center for Epidemiologic Studies Depression Scale preoperatively and at 3, 6, 12, and 24 months postoperatively. They reported a median survival of 3.4 years; 1, 3, and 5-year survivals were 77.4, 55.2, and 36.5%, respectively. Between 3 months and 1 year following surgery, patients achieved baseline QOL or had QOL improved from baseline. Patients may tolerate HIPEC well and have good overall QOL postoperatively despite the risks linked with this procedure.